BioSpace News Archive

Promontory Therapeutics Inc. , a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced the appointment of Johan Baeck, MD, as Executive Vice President and Chief Medical Officer.

Commercialization of Accelerate Arc system, which includes the Accelerate Arc Module and BC kit, unlocks the path to automated, rapid microbial ID for positive blood cultures across the large installed base of MALDI system users.

CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update.

Alvotech Holdings S.A. today announced positive top-line results from a pharmacokinetic (PK) study for AVT04, Alvotech’s proposed biosimilar to to Stelara® (ustekinumab).

Catamaran Bio , Inc., a biotechnology company developing off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, is presenting new preclinical data today at the American Society of Gene and Cell Therapy.

Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced the formation of its Scientific Advisory Board (SAB) comprised of an esteemed group of leading scientists with expertise in protein degradation, chemistry, genetics, and drug discovery.

Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meeting.

Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the quarter ended March 31, 2022.

Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced a key opinion leader (KOL) presentation and a live-case event featuring the Company’s Lumivascular technology at two important vascular conferences in Germany.

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its Fiscal Year Q3 ended March 31, 2022.